Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Treatment of Newly Diagnosed Childhood Acute Myeloid Leukemia (AML) Using Intensive MRC-Based Therapy and Gemtuzumab Ozogamicin (GMTZ): A COG Pilot Study

NCT00070174 is registered in ClinicalTrials.gov with Children's Oncology Group as lead sponsor.

NCT NCT00070174
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00070174 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Treatment of Newly Diagnosed Childhood Acute Myeloid Leukemia (AML) Using Intensive MRC-Based Therapy and Gemtuzumab Ozogamicin (GMTZ): A COG Pilot Study
Lead sponsor
Children's Oncology Group
Phase
Phase 2
Overall status
Completed
Start date
December 31, 2003
Completion date
December 31, 2013
Enrollment
350 (actual)
Sites
148

Conditions

As the registry lists them; a condition with its own page is linked.

leukemia